% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. Message Board

  • jfk123_1 jfk123_1 Sep 12, 2013 1:13 PM Flag

    It is important to note that:

    Fast Track status is a bit of a gimmick - i.e. it has no impact or relevance relating to the likelihood of a drug being accepted. And analysts almost never upgrade or even pay attention to an announcement of Fast Track status. Actually, many people who are long the stock and want to get out, or shorts who want to double up, use the blip caused by the Fast Track announcement and day traders doing the knee jerk buy as an opportunity to sell and increase their short position or take profits. However, here it is a bit different, as the news for the new platform has yet to be reflected in the share price because the share price is weighed down by heavy discounting and bets against the eventual approval of Ganetespib. Announcing the Fast Track after yesterday's investor call simply shows that Gan. is all go at the moment from the company's point of view, which can allow investors to bid up the shares and price in the platform announcement. The massive shorting effort today, simply works into setting up the squeeze as the platform announcement and lack of bad news on Ganet. now needs to be priced into a higher share price.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
2.06+0.08(+4.04%)4:00 PMEDT